Cervical cancer is the second most common cancer in Women of India, which continues to remain one of the biggest preventable public health challenges. India records over 1.2 lakh new cervical cancer cases annually and nearly 80,000 deaths, making it one of the leading causes of cancer mortality among Indian women.
The most obvious and defining feature of cervical cancer is a persistent infection with high-risk types of the human papillomavirus (HPV), which makes vaccination important for prevention. However, for many years, HPV vaccination in India remained limited due to its higher costs, lack of awareness among women, and the absence of large-scale public immunisation programmes.
For decades, cervical cancer control in India has largely depended on screening and treatment. But screening coverage has remained limited, particularly in rural and underserved regions. As a result, many women still reach hospitals only when the disease has already advanced. This is why the expansion of HPV vaccination initiatives marks an important transition in how we approach the control.
As per the findings and research, 99 per cent of cervical cancer cases are associated with persistent infection with high-risk HPV strains, particularly 70 per cent because of the HPV-16 and HPV-18. Vaccination works by preventing infection from these cancer-causing strains. The vaccine for treating cervical cancer is most effective when administered before exposure to the virus in the body.
We can see the measurable results in countries that introduced large-scale HPV vaccination programmes more than a decade ago as Australia, the United Kingdom, and parts of Europe, have reported reductions of up to 80-90 per cent in HPV infections and precancerous cervical lesions among vaccinated populations. It shows that vaccination is not only a preventive intervention but also a long-term cancer control strategy.
India’s nationwide HPV vaccination campaign, launched in 2026, represents one of the most significant preventive health initiatives focused on women’s cancers. The programme aims to vaccinate approximately 1.15 crore girls aged 14 years every year through government health facilities, and the vaccine Gardasil-4 is to protect against four HPV types, including HPV-16 and HPV-18, which are responsible for most cervical cancers. Providing the vaccine through government health facilities is particularly important, as cost has historically been a major barrier for lower and middle-class families.
The move also aligns India with a growing global trend. More than 160 countries have already incorporated HPV vaccination into their national immunisation schedules, recognising it as a central pillar of cervical cancer prevention strategies. Countries that adopted vaccination early are now beginning to see the long-term benefits, including reductions in HPV infections and precancerous cervical lesions among young women.
From a public health perspective, the scale of this campaign is particularly significant. Immunising a large adolescent cohort each year could gradually reduce HPV circulation within the population, lowering infection risk for future generations.
Another encouraging development in India’s vaccination journey is the emergence of indigenously developed HPV vaccines, which promise to make large-scale immunisation more affordable and sustainable.
Until recently, HPV vaccines available in India were largely imported and relatively expensive, placing them beyond the reach of many families. Domestic vaccine development has the potential to change that equation by lowering costs and strengthening supply. India’s long-standing expertise in vaccine manufacturing has already played a major role in global immunisation programmes. Applying that strength to HPV vaccination could ensure that preventive protection becomes accessible to millions more adolescents across the country.
Early vaccination is a powerful tool against cervical cancer, but the women who are already adults and may have been exposed to HPV still require regular screening, such as Pap smears or HPV testing. Unfortunately, the costs for cancer screenings in India are extremely low, yet the factors such as Cultural stigma, lack of awareness, and limited access to healthcare facilities continue to prevent many women from undergoing routine screening.
Addressing cervical cancer requires a comprehensive strategy that combines vaccination, screening, and timely treatment. The need to build public awareness is also equally important. Conversations around HPV vaccination are still often surrounded by hesitation or misunderstanding. Healthcare professionals, educators, and community health workers must play an active role in communicating that the HPV vaccine is fundamentally a cancer-prevention vaccine.
The World Health Organization’s cervical cancer elimination strategy, also one of the most influential against cervical cancer, which is often referred to as the 90-70-90 framework, aims to achieve the following targets by 2030:
Achieving these targets globally could prevent up to 74 million cervical cancer cases and 62 million deaths by 2120, highlighting the long-term impact of coordinated prevention efforts.
India’s immunisation tracking system is another important aspect of the vaccination initiative, as a part of the digital health infrastructure. U-WIN is designed to monitor vaccine delivery, beneficiary registration, and dose completion in real time. The platform builds on the digital architecture developed during the COVID-19 vaccination campaign, and such systems allow public health authorities to identify coverage gaps, monitor vaccine uptake, and improve accountability across large immunisation programmes.
Oncologists in India have been focused on improving treatments for cervical cancer for years by using better surgeries, effective chemotherapy, and advanced radiation techniques. While these advancements have saved many lives, the ultimate goal has always been to prevent the disease from occurring in the first place.
Yet, Vaccination initiatives and recent government-led programmes are beginning to move the conversation in a more influential direction. By vaccinating young girls at an early age, these efforts have the potential to significantly reduce the number of women who may ever face a cervical cancer diagnosis later in life.
So vaccination initiatives are long-term efforts for the health and dignity of women across the country. And perhaps for the first time in the history of this disease, if these initiatives continue to expand alongside stronger awareness and screening programmes, India could realistically move toward reducing and perhaps one day eliminating the burden of cervical cancer.
